Effectiveness of SGLT2 inhibitors in slowing chronic kidney disease progression and reducing mortality: a meta-analysis

BackgroundChronic kidney disease (CKD) represents a significant health problem worldwide with high morbidity, mortality, and development of end-stage kidney disease (ESKD). Sodium-glucose co-transporter 2 (SGLT2) inhibitors represent an innovative class of medications with possible cardiorenal advan...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Arjun Sharma, Bharat Sharma, Deepthi Sree Vamaraju, Amrendra Kumar Ajay
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2026-08-01
Serie:	Frontiers in Pharmacology
Soggetti:	chronic kidney disease (CKD) end-stage kidney disease (ESKD) estimated glomerular filtration rate (eGFR) renal progression SGLT2 inhibitors
Accesso online:	https://www.frontiersin.org/articles/10.3389/fphar.2026.1923548/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!